78 related articles for article (PubMed ID: 38441358)
1. Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands.
Wakefield DL; Golfetto O; Jorand R; Biswas S; Meyer K; Avery KN; Zer C; Cacao EE; Tobin SJ; Talisman IJ; Williams JC; Jovanovic-Talisman T
Front Med (Lausanne); 2023; 10():1064242. PubMed ID: 37138747
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.
Blas PE; Rodriguez ESR; Williams HL; Levin MK; Bell JSK; Pierobon M; Barrett AS; Petricoin EF; O'Shaughnessy JA
Cancer Rep (Hoboken); 2024 Mar; 7(3):e1954. PubMed ID: 38441358
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
5. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
6. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
[TBL] [Abstract][Full Text] [Related]
8. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K; Eli LD; Wildiers H; Hurvitz SA; Guerrero-Zotano A; Unni N; Brufsky A; Park H; Waisman J; Yang ES; Spanggaard I; Reid S; Burkard ME; Vinayak S; Prat A; Arnedos M; Bidard FC; Loi S; Crown J; Bhave M; Piha-Paul SA; Suga JM; Chia S; Saura C; Garcia-Saenz JÁ; Gambardella V; de Miguel MJ; Gal-Yam EN; Rapael A; Stemmer SM; Ma C; Hanker AB; Ye D; Goldman JW; Bose R; Peterson L; Bell JSK; Frazier A; DiPrimeo D; Wong A; Arteaga CL; Solit DB
Ann Oncol; 2023 Oct; 34(10):885-898. PubMed ID: 37597578
[TBL] [Abstract][Full Text] [Related]
9. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
Koyama K; Ishikawa H; Abe M; Shiose Y; Ueno S; Qiu Y; Nakamaru K; Murakami M
PLoS One; 2022; 17(5):e0267027. PubMed ID: 35503762
[TBL] [Abstract][Full Text] [Related]
10. Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.
Pierobon M; Robert NJ; Northfelt DW; Jahanzeb M; Wong S; Hodge KA; Baldelli E; Aldrich J; Craig DW; Liotta LA; Avramovic S; Wojtusiak J; Alemi F; Wulfkuhle JD; Bellos A; Gallagher RI; Arguello D; Conrad A; Kemkes A; Loesch DM; Vocila L; Dunetz B; Carpten JD; Petricoin EF; Anthony SP
Mol Oncol; 2022 Jan; 16(1):104-115. PubMed ID: 34437759
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.
Gonzalez-Ericsson PI; Wulfkhule JD; Gallagher RI; Sun X; Axelrod ML; Sheng Q; Luo N; Gomez H; Sanchez V; Sanders M; Pusztai L; Petricoin E; Blenman KRM; Balko JM;
Clin Cancer Res; 2021 Oct; 27(19):5299-5306. PubMed ID: 34315723
[TBL] [Abstract][Full Text] [Related]
12. Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.
Parmar S; Keck JM; Kong B; Look R; Johnson B; Patterson J; Labrie M; Guimaraes AR; Corless CL; Beadling C; Kolodzie A; Bergan R; Gray JW; Mills GB; Mitri ZI
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250408
[No Abstract] [Full Text] [Related]
13. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Hanker AB; Brown BP; Meiler J; Marín A; Jayanthan HS; Ye D; Lin CC; Akamatsu H; Lee KM; Chatterjee S; Sudhan DR; Servetto A; Brewer MR; Koch JP; Sheehan JH; He J; Lalani AS; Arteaga CL
Cancer Cell; 2021 Aug; 39(8):1099-1114.e8. PubMed ID: 34171264
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]